Shares of Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) were down 0.3% during mid-day trading on Thursday . The stock traded as low as C$8.55 and last traded at C$8.62. Approximately 200 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 2,031 shares. The stock had previously closed at C$8.65.
Wall Street Analyst Weigh In
Separately, Stephens raised Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
Read Our Latest Stock Report on FRX
Fennec Pharmaceuticals Stock Performance
The firm has a market capitalization of C$237.48 million, a price-to-earnings ratio of 86.80 and a beta of 0.25. The firm's 50-day moving average price is C$6.88 and its two-hundred day moving average price is C$7.72. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02.
Insider Activity
In related news, Senior Officer Robert Christopher Andrade bought 15,816 shares of the business's stock in a transaction dated Monday, November 18th. The stock was bought at an average price of C$3.43 per share, for a total transaction of C$54,248.88. 16.20% of the stock is currently owned by company insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
See Also
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
